comparemela.com
Home
Live Updates
Pharmacoeconomics Open - Breaking News
Pages:
Latest Breaking News On - Pharmacoeconomics open - Page 1 : comparemela.com
Intersect ENT, Inc : Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat ("ENT") medical
United kingdom
Randy meier
Erich sandoval
Jan gosepath
Exchange commission
Intersect ent inc
Department of otolaryngology
European union
Securities exchange
Neck surgery
Medical director
Helios private clinic
Chief executive officer
Securities act
Securities exchange act
Chronic rhinosinusitis an update
vimarsana © 2020. All Rights Reserved.